Global Controlled Trial on Effects of an Online Self-Help Program for of Ambitious Altruists on Their Mental Health, Wellbeing, and Productivity: Comparing Versions With IFS vs. CBT, Buddy- vs. Group-, Standard- vs. Minimum-Guidance Intensity.
Launched by RETHINK WELLBEING · May 29, 2024
Trial Information
Current as of March 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Aim:
This study aims to compare different versions of an online self-help program in terms of their effect on self-assessed mental health, well-being, and productivity. The goal is to find out if a version might be more effective or similarly effective but less costly than the original one.
Control groups:
The original program version is an 8-week course with weekly guided group sessions of 2 hours: Third Wave CBT methods are taught by a workbook and practised in between the sessions. The pre-post results, on 42 ambitious altruists, showed significant moderate effects on all scales after...
Gender
ALL
Eligibility criteria
- Exclusion Criteria:
- • average of self-assessed sociality negative
- • people in acute crisis (they confirm and sign to not be in such a state)
- • people who self-report not to be ambitiously altruistic, i.g., not involved in the effective altruism community, or working on or planning to work on something impactful that might help others.
Trial Officials
Inga Grossmann, PhD.
Study Director
Rethink Wellbeing
About Rethink Wellbeing
Rethink Wellbeing is a forward-thinking clinical trial sponsor dedicated to advancing mental health and wellness through innovative research and evidence-based interventions. Committed to enhancing the quality of life for individuals, Rethink Wellbeing focuses on developing and evaluating novel therapeutic approaches that address a wide range of psychological and emotional challenges. By fostering collaboration with healthcare professionals, researchers, and communities, the organization aims to drive transformative change in the mental health landscape, ultimately contributing to improved outcomes and greater accessibility to care for those in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wapenveld, , Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
